Company: CRNX
Filing Date: 2025-04-23
Form Type: DEF 14A
Source: 0000950170-25-057452
Chunk: 59

Company: Crinetics Pharmaceuticals, Inc.
Filing Date: 2025-04-23
Form: DEF 14A
Chunk 59
---
 management and other employees that mitigate potential risks to us that could arise from our compensation program. Following the assessment, management determined that our compensation policies and practices did not create risks that were reasonably likely to have a material adverse effect on us and reported the results of the assessment to our compensation committee. Report of the Compensation Committee of the Board of Directors The compensation committee of our board of directors has submitted the following report for inclusion in this proxy statement: The compensation committee has reviewed and discussed with management the Compensation Discussion and Analysis set forth above. Based on such review and discussions, the compensation committee has recommended to the board of directors that the Compensation Discussion and Analysis be included in this proxy statement and in the Annual Report on Form 10-K for the year ended December 31, 2024, filed by us with the SEC. This report of the compensation committee is not “soliciting material,” shall not be deemed “filed” with the SEC and shall not be incorporated by reference by any general statement incorporating by reference this proxy statement into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date hereof and irrespective of any general incorporation language in any such filing, except to the extent that we specifically incorporate this information by reference, and shall not otherwise be deemed filed under such acts. The foregoing report has been furnished by the compensation committee.

| Respectfully submitted,                              |
| The Compensation Committee of the Board of Directors |
| Stephanie S. Okey, M.S. (Chair)                      |
| Matthew K. Fust                                      |
| Wendell Wierenga, Ph.D.                              |

<div align='center'>44</div>

Summary Compensation Table The following table shows information regarding the compensation earned by our named executive officers during the years ended December 31, 2024, 2023 and 2022.

|                                       |     |      |     |  Salary |     |  Bonus |    | Stock Awards |     | Option Awards |     | Non-Equity Incentive Plan Compensation |     | All Other Compensation |    |      Total |
| Name and Principal Position           |     | Year |     |      -$ |     |     -$ |    |        -$)(1 |     |         -$)(1 |     |                                  -$)(2 |     |                  -$)(3 |    |         -$ |
| R. Scott Struthers, Ph.D.             |     | 2024 |